ScinoPharm Taiwan Ltd
TWSE:1789
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23
29.45
|
| Price Target |
|
We'll email you a reminder when the closing price reaches TWD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
ScinoPharm Taiwan Ltd
ScinoPharm Taiwan Ltd
Accounts Receivables
ScinoPharm Taiwan Ltd
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Accounts Receivables
NT$478.6m
|
CAGR 3-Years
10%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-5%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Accounts Receivables
NT$1.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
3%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Accounts Receivables
NT$1.2B
|
CAGR 3-Years
19%
|
CAGR 5-Years
8%
|
CAGR 10-Years
4%
|
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Accounts Receivables
NT$368.8m
|
CAGR 3-Years
39%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
7%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Accounts Receivables
NT$6.1B
|
CAGR 3-Years
15%
|
CAGR 5-Years
27%
|
CAGR 10-Years
20%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Accounts Receivables
NT$1.1B
|
CAGR 3-Years
13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
8%
|
|
ScinoPharm Taiwan Ltd
Glance View
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
See Also
What is ScinoPharm Taiwan Ltd's Accounts Receivables?
Accounts Receivables
478.6m
TWD
Based on the financial report for Jun 30, 2024, ScinoPharm Taiwan Ltd's Accounts Receivables amounts to 478.6m TWD.
What is ScinoPharm Taiwan Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
-5%
Over the last year, the Accounts Receivables growth was -14%. The average annual Accounts Receivables growth rates for ScinoPharm Taiwan Ltd have been 10% over the past three years , 2% over the past five years , and -5% over the past ten years .
You don't have any saved screeners yet
